Thus comparing two NPC patients where one has high MTSS1 expression and the other one has low MTSS1 expression, the model predicts a better prognosis (i.e., survival) for patients with high MTSS1 expression in 64% of cases, while lower expression of MTSS1 correlated with a worse prognosis for these patients with NPC. The gene discussed is MTSS1; the disease is nasopharyngeal carcinoma.